AUDREY HOUSMAN: Open Payments
NPI 1932732203 · DAVENPORT, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$813 in 46 payments from 16 companies in 2025. Trend: 2023 $388 · 2024 $545 · 2025 $813
Food & beverage: $813
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $187 |
| Lilly USA, LLC | 5 | $104 |
| PFIZER INC. | 5 | $83 |
| AstraZeneca Pharmaceuticals LP | 4 | $73 |
| Amgen Inc. | 4 | $68 |
| Dexcom, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Novo Nordisk Inc | 1 | $23 |
Products named: VRAYLAR, MOUNJARO, JARDIANCE, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, CAPLYTA, QULIPTA.
Industry payments across IA — which companies pay providers there.
